Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving NivolumabDavid F. McDermott, Michael B. Atkins, Charles G. Drake et al.|Journal of Clinical Oncology|2015Cited by 443
Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer MicroenvironmentJohn T. Isaacs, Tomas Leanderson, Stephanie Gerber et al.|Cancer Research|2012Cited by 113
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)Michael B. Atkins, Hans J. Hammers|Journal for ImmunoTherapy of Cancer|2023Cited by 30